Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 13.125 GBX Market Closed
Market Cap: 54.1m GBX
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+78%
Revenue
Forecast
+8%
Operating Income
Forecast
+20%
Net Income
Forecast
+36%

Wall Street
Price Targets

CREO Price Targets Summary
Creo Medical Group PLC

Wall Street analysts forecast CREO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CREO is 58.65 GBX with a low forecast of 45.45 GBX and a high forecast of 73.5 GBX.

CREO Lowest Forecast
Wall Street Target
45.45 GBX
246% Upside
CREO Average Forecast
Wall Street Target
58.65 GBX
347% Upside
CREO Highest Forecast
Wall Street Target
73.5 GBX
460% Upside
Lowest
Price Target
45.45 GBX
246% Upside
Average
Price Target
58.65 GBX
347% Upside
Highest
Price Target
73.5 GBX
460% Upside
Creo Medical Group PLC Competitors:
Price Targets
IRMD
IRadimed Corp
37% Upside
M
179290
MITech Co Ltd
78% Upside
NNOX
Nano-X Imaging Ltd
159% Upside
PODD
Insulet Corp
19% Upside
IRMD
IRadimed Corp
37% Upside
M
179290
MITech Co Ltd
78% Upside
NNOX
Nano-X Imaging Ltd
159% Upside
PODD
Insulet Corp
19% Upside
SOON
Sonova Holding AG
15% Upside
MDT
Medtronic PLC
11% Upside
S
STIL
Stille AB
21% Upside
ZBH
Zimmer Biomet Holdings Inc
12% Upside

Revenue
Forecast

Revenue Estimate
Creo Medical Group PLC

The compound annual growth rate of Creo Medical Group PLC's revenue for the next 4 years is -10%.

N/A
Past Growth
-10%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Creo Medical Group PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Creo Medical Group PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss
What are analyst estimates?

See Also

Summary
CREO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CREO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CREO stock valuation using valuation multiples.
Wall Street Estimates
CREO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CREO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CREO's stock price target?
Price Target
58.65 GBX

According to Wall Street analysts, the average 1-year price target for CREO is 58.65 GBX with a low forecast of 45.45 GBX and a high forecast of 73.5 GBX.

What is Creo Medical Group PLC's Revenue forecast?
Projected CAGR
-10%

The compound annual growth rate of Creo Medical Group PLC's revenue for the next 4 years is -10%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 241,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.